Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.
A study by Oregon Health & Science University researchers has uncovered a new way proteins can be changed inside cells. This ...
The University of Arkansas for Medical Sciences (UAMS) researcher Kevin Raney, Ph.D., has been awarded a five-year, $2.99 ...
Richardson, has published promising findings from the past seven years of research into a new approach for the treatment of ...
When your social media account starts spewing out nonsensical or threatening status updates, it's safe to assume that it has ...
The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 ...
Dave Coulier was diagnosed with Stage 3 non-Hodgkin lymphoma, a type of blood cancer that starts in the lymphatic system.
It may seem unusual to discuss future fertility when a family is reeling from the diagnosis of a child’s cancer. But 85% of ...
Carrillo, MD, evaluates the current state of the global availability of clinical trials for patients with renal cell ...
FDA approved AstraZeneca's Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma.
The firm previously said it will test the CER T-cell therapy CER-1236 in blood cancers after receiving FDA manufacturing clearance.
chemotherapy amid his ongoing battle with stage 3 non-Hodgkin’s lymphoma, a cancer in the lymphatic system. In a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback